Patterns of resistance mutations to antiretroviral drugs in extensively treated hiv-1-infected patients with failure of highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 1, 2001, Pages 36-43

  Rousseau, Marie Noelle ^a   Vergne, Laurence ^b   Montes, Brigitte ^a   Peeters, Martine ^b   Reynes, Jacques ^a   Delaporte, Eric ^a,b   Segondy, Michel ^a,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

Genotypic resistance; Highly active antiretroviral therapy; Mutations; Treatment failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CODON; CROSS RESISTANCE; GENE INSERTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS MUTATION;

EID: 0035141058     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200101010-00005     Document Type: Article

References (26)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
2. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection
3. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
4. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
5. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment
6. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
7. Tests de résistance aux antirétroviraux
8. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors
9. Impact of drug resistance mutations on virologic responses to salvage therapy
10. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
11. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
12. Genotypic and phenotypic correlation of response to abacavir (ABC, 1592)
13. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
14. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
15. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
16. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
17. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
18. Drug-resistance genotyping in HIV-1 therapy: The Viradept randomised controlled trial
19. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences
20. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years
21. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
22. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
23. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure
24. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
25. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV1 reverse transcriptase from extensively treated patients: Incidence and association with other mutations
26. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high level of cross-resistance to nucleoside reverse transcriptase inhibitors